CNS

  • Interview with Dr. Andrew Cutler25:31

    Interview with Dr. Andrew Cutler

    Dr. Cutler shares his insights on the current challenges and opportunities for CNS therapies and clinical trials during an energizing conversation with Dr. Mark Opler.

    Watch Video
  • Q&A with CNS Expert, Dr. Philip Scheltens

    Q&A with CNS Expert, Dr. Philip Scheltens

    Philip Scheltens, MD, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Christopher Randolph, PhD, ABPP-CN, chief scientific officer...

    Read Flipbook
  • Q&A with Dr. Sofija Jovic

    Q&A with Dr. Sofija Jovic

    Increasingly, sponsors are turning to experts who have “been there, done that” to help them develop protocols for their CNS trials. In this wide-ranging interview, Sofija Jovic, PhD, MBA, of WCG...

    Read Flipbook
  • Q&A with CNS Expert, Dr. Leo Verhagen Metman

    Q&A with CNS Expert, Dr. Leo Verhagen Metman

    Leo Verhagen Metman, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation...

    Read Flipbook
  • Addressing Suggestibility as a Psychological Phenomenon in Clinical Trials

    Addressing Suggestibility as a Psychological Phenomenon in Clinical Trials

    It is important to understand patient perspectives and to anticipate how subjects in research studies may be impacted by the presence of digital tools, devices, and mobile health applications

    Read Flipbook
  • Interview with Dr. Leslie Citrome14:37

    Interview with Dr. Leslie Citrome

    Watch Video
  • Improving Subject Selection and Endpoint Management in Alzheimer's Trials

    Improving Subject Selection and Endpoint Management in Alzheimer's Trials

    Read Flipbook
  • Increased Signal Detection in Alzheimer's Disease Clinical Trials

    Increased Signal Detection in Alzheimer's Disease Clinical Trials

    This study investigated the impact of lag time on error rates for commonly used Alzheimer’s disease COAs, as well as the degree to which administration attenuated error rates associated with lag time.

    Read Flipbook
  • Interview with Dr. Cristoph Correll14:37

    Interview with Dr. Cristoph Correll

    Christoph Correll, MD, a member of WCG’s Scientific Leadership Team, shares his thoughts on the most important trends in CNS clinical trials and what lies ahead in 2019

    Watch Video
  • Q&A with CNS Expert, Dr. Michael Liebowitz

    Q&A with CNS Expert, Dr. Michael Liebowitz

    Dr. Michael Liebowitz, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...

    Read Flipbook
  • Genetic Counselors at the Forefront of Helping Researchers Brace for the "Silver Tsunami" of CNS Disorders

    Genetic Counselors at the Forefront of Helping Researchers Brace for the "Silver Tsunami" of CNS Disorders

    An aging population is triggering a “silver tsunami” of neurodegenerative diseases like Alzheimer’s and Parkinson. At the same time, precision medicine holds great promise for many CNS disorders.

    Read Flipbook
  • Q&A with CNS Expert, Dr. Leslie Citrome

    Q&A with CNS Expert, Dr. Leslie Citrome

    Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

    Read Flipbook
  • 2018 Tufts CSDD IMPACT Report for CNS

    2018 Tufts CSDD IMPACT Report for CNS

    This report summarizes a recent Tufts CSDD analysis of 509 drugs and biologics that received FDA approval from 2000 to 2017.

    Read Flipbook
  • Q&A with CNS Expert, Dr. Christoph U. Correll

    Q&A with CNS Expert, Dr. Christoph U. Correll

    Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

    Read Flipbook
  • WCG MedAvante-ProPhase Adds Prominent Thought Leaders to its CNS Scientific Leadership Team

    WCG MedAvante-ProPhase Adds Prominent Thought Leaders to its CNS Scientific Leadership Team

    The WCG Clinical Services Division has added eight internationally recognized thought leaders to its Scientific Leadership Team.

    Read Flipbook
  • eCOA: Keep it Simple, Exec Argues

    eCOA: Keep it Simple, Exec Argues

    Nearly half of all clinical trials still use paper as the primary - or even sole - source of records while barely a quarter of trials use eCOA or ePRO

    Read Flipbook
  • Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions

    Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions

    In this article, the authors review the methods for ensuring reliability of the PANSS as well as a proposed trajectory for its use in the future.

    Read Flipbook
  • Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

    Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

    The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.

    Read Flipbook
  • Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients with Uncomplicated Mild Traumatic Brain Injury or Non-Traumat

    Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients with Uncomplicated Mild Traumatic Brain Injury or Non-Traumat

    The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.

    Read Flipbook
  • Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility

    Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility

    Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer’s disease (AD).

    Read Flipbook
  • loading
    Loading More...